- Imagin Medical believes the i/Blue System can revolutionize the current standard of care for bladder cancer patients by improving cancer visualization for removal, and potentially lowering recurrence rates
- Imagin Medical is leveraging the significant expertise in optics, electronics, software, and mechanical design of FDA-registered contract manufacturer, Lighthouse Imaging, to implement the final stage of the i/Blue(TM) Imaging System
- Lighthouse’s manufacturing program remains on track for product commercialization in 2022
Surgical imaging company
Imagin Medical (CSE: IME) (OTCQB: IMEXF) is continuing progress with the commercial-stage manufacturing of its patented i/Blue Imaging System, an innovative technology that the company believes will revolutionize the way surgeons visualize the bladder and identify cancers during minimally invasive surgery. The company has been working with contract manufacturer, Lighthouse Imaging, to complete the system for commercialization.
In a company press release, Imagin Medical’s President and CEO, Jim Hutchens, said the COVID-19 pandemic impacted the company’s production timeline by approximately nine months, which moved product completion into…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at
https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the
InvestorBrandNetwork.